Jason Chia-Hsun Hsieh1, Cheng-Lung Hsu2, Shu-Hang Ng3, Cheng-Hsu Wang4, Kuan-Der Lee5, Chang-Hsien Lu5, Yi-Fang Chang6, Ruey-Kuen Hsieh6, Kun-Huei Yeh7, Chi-Huang Hsiao8, Sheng-Yu Chen9, Cheng-Ying Shiau10, Hung-Ming Wang11. 1. Division of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan Department of Chemical and Materials Engineering, Chang Gung University, Taoyuan. 2. Division of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan. 3. Department of Diagnostic Radiology, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan. 4. Division of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Keelung and Chang Gung University, Taoyuan. 5. Division of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Chiayi and Chang Gung University, Taoyuan. 6. Department of Hematology and Oncology, Taipei Cancer Center, Taipei Medical University, Taipei. 7. Department of Oncology, National Taiwan University and Hospital, Taipei. 8. Division of Oncology and Hematology, Department of Internal Medicine, Far Eastern Hospital, Taipei. 9. Cancer Center, Chemoradiotherapy Division, Taipei Veterans General Hospital, Taipei. 10. Cancer Center, Radiation Oncology Division, Taipei Veterans General Hospital, Taipei, Taiwan. 11. Division of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan whm526@adm.cgmh.org.tw.
Abstract
OBJECTIVE: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. METHODS: Gemcitabine 1250 mg/m(2) on Days 1 and 8 and cisplatin 75 mg/m(2) on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. RESULTS: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9% (complete remission rate, 9.6%) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6%). The mean number of cycles was 6.63 ± 0.40. The regimen was well-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. CONCLUSIONS: Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.
OBJECTIVE: This multicenter Phase II trial evaluated the toxicity/efficacy of gemcitabine plus cisplatin as first-line chemotherapy in patients with recurrent/metastatic nasopharyngeal carcinoma. METHODS:Gemcitabine 1250 mg/m(2) on Days 1 and 8 and cisplatin 75 mg/m(2) on Day 1 were administered at a 3-week interval. The primary endpoint was the response rate. Secondary endpoints included progression-free survival, overall survival, response duration and safety. RESULTS: Fifty-two patients were recruited between 2004 and 2008. The response rate was 51.9% (complete remission rate, 9.6%) in the intent-to-treat group. The median progression-free and overall survivals were 9.8 and 14.6 months, respectively. The major Grade III/IV adverse event was leucopenia (61.6%). The mean number of cycles was 6.63 ± 0.40. The regimen was well-tolerated, although one treatment-related death occurred after severe sepsis from aspiration pneumonia. CONCLUSIONS:Gemcitabine plus cisplatin is an effective, well-tolerated regimen as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma.
Authors: Richard Du; Victor H Lee; Hui Yuan; Ka-On Lam; Herbert H Pang; Yu Chen; Edmund Y Lam; Pek-Lan Khong; Anne W Lee; Dora L Kwong; Varut Vardhanabhuti Journal: Radiol Artif Intell Date: 2019-07-10
Authors: Victor H F Lee; Dora L W Kwong; Ka-On Lam; Yu-Ching Lai; Yun Li; Chi-Chung Tong; Patty P Y Ho; Wing-Lok Chan; Lai-San Wong; Dennis K C Leung; Sum-Yin Chan; Fong-Ting Chan; To-Wai Leung; Anne W M Lee Journal: Medicine (Baltimore) Date: 2017-04 Impact factor: 1.889